Trevi Therapeutics (TRVI) Change in Cash (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Change in Cash of $498000.0 for Q1 2026, up 103.38% year-over-year from $244858.9 in Q1 2025, and up 101.31% quarter-over-quarter from -$38.0 million in Q4 2025.
Analysis
Trevi Therapeutics (TRVI) Change in Cash (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Change in Cash history runs 9 years deep, the most recent figure standing at $498000.0 for Q1 2026.
- In Q1 2026, Change in Cash rose 103.38% year-over-year to $498000.0; the TTM figure through Mar 2026 stood at $38000.0 (down 99.32% YoY), while the FY2025 annual figure was -$15.2 million, down 993.12% from the prior year.
- Change in Cash for Q1 2026 stood at $498000.0, up from -$38.0 million in the prior quarter.
- The five-year high for Change in Cash was $97.7 million in Q2 2025, with the low at -$60.2 million in Q3 2025.
- The 5-year median for Change in Cash is -$848000.0 (2024), against an average of -$1.0 million.
- Peak annual rise in Change in Cash reached 11619.34% in 2025, while the deepest fall reached 2048.49% in 2025.
- Trevi Therapeutics' Change in Cash stood at -$54.0 million in 2022, then soared by 111.91% to $6.4 million in 2023, then surged by 180.55% to $18.0 million in 2024, then sank by 310.34% to -$38.0 million in 2025, then soared by 101.31% to $498000.0 in 2026.
- Business Quant data shows TRVI's Change in Cash at $498000.0 in Q1 2026, -$38.0 million in Q4 2025, and -$60.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - | 34.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.89 Mn |
| Mar 31, 2026 | 498,000.00 |
| Dec 31, 2025 | -37.96 Mn |
| Sep 30, 2025 | -60.19 Mn |
| Jun 30, 2025 | 97.68 Mn |
| Mar 31, 2025 | -14.72 Mn |
| Dec 31, 2024 | 18.05 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | -848,000.00 |
| Mar 31, 2024 | -18.59 Mn |
| Dec 31, 2023 | 6.43 Mn |
| Sep 30, 2023 | 12.21 Mn |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | -938,000.00 |
| Dec 31, 2022 | -53.99 Mn |
| Sep 30, 2022 | 41.88 Mn |
| Jun 30, 2022 | -4.42 Mn |
| Mar 31, 2022 | -7.72 Mn |
| Dec 31, 2021 | 7.51 Mn |
| Sep 30, 2021 | -7.11 Mn |